International Journal of Endocrinology / 2016 / Article / Tab 3

Review Article

Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials

Table 3

Biochemical and clinical findings related to hyperandrogenism and metabolism.

RefTreatmentTestosterone (ng/dL)Androstenedione (ng/mL)Free testosterone (ng/dL)Insulin (µU/mL)HOMA indexOGTTSHBG (nmol/L)General findings

[20]Myo-Ins
versus
FA
54.8 ± 6.2
versus
55.2 ± 9.1
1.70 ± 0.29
versus
1.91 ± 0.24
NA6.5 ± 1.1
versus
11.3 ± 1.1
1.4 ± 0.3
versus
2.5 ± 0.7
Myo-Ins improved glucose toleranceNAMyo-Ins significantly reduced LH, PRL, insulin levels, and LH/FSH ratio and significantly improved insulin sensitivity and menstrual cyclicity was restored in amenorrheic and oligomenorrheic subjects.

[21]Myo-Ins
versus
FA
34.8 ± 4.3
versus
109.0 ± 7.5
1.96 ± 0.26
versus
3.06 ± 0.41
0.24 ± 0.03
versus
0.85 ± 0.13
26.0 ± 8.0
versus
38.0 ± 7.0
NAMyo-Ins improved glucose tolerance198.0 ± 24.0
versus
163.0 ± 26.0
Myo-Ins increased insulin sensitivity and improved glucose tolerance and insulin release. There was a significant reduction in total and free T. There was a decrement in systolic and diastolic blood pressure. Plasma triglycerides and total cholesterol concentration decreased.

[10]Myo-Ins
versus
placebo
101.0 (81–121)
versus
121.0 (101–141)
Decreased in Myo-Ins groupNANo significant differenceNANo significant difference36.5
versus
26.3
Myo-Ins showed a beneficial effect in improving ovarian function in PCOS women with oligomenorrhea.

[11]Myo-Ins
versus
FA
95.0 (72–115)
versus
118.0 (98–138)
Decreased in Myo-Ins groupNA16.8
versus
17.3
NANo significant difference35.9
versus
25.8
Myo-Ins treatment showed a beneficial effect in improving ovarian function, anthropometric measures,
and lipid profile.

[22]Myo-Ins + D-chiro-Ins
versus
Myo-Ins
32.7 ± 10.0
versus
40.1 ± 9.5
1.94 ± 0.15
versus
1.98 ± 0.19
0.23 ± 0.02
versus
0.24 ± 0.03
9.2 ± 2.1
versus
9.6 ± 1.9
1.5 ± 0.28
versus
1.9 ± 2.1
Myo-Ins + D-chiro-Ins improved glucose tolerance208 ± 20
versus
202 ± 27
Both treatments, Myo-Ins + D-chiro-Ins, or Myo-Ins alone normalized the metabolic parameters and restored ovulation in overweight PCOS women. At the end of the treatment both the fasting insulin and glucose serum concentration level were significantly reduced. However, compared to Myo-Ins alone, the combined treatment has shown significant changes on the metabolic profile after only 12 weeks.

[23]Myo-Ins + D-chiro-Ins
versus
Myo-Ins
NA4.01 ± 1.7
versus
3.12 ± 2.23
0.62 ± 0.15
versus
0.83 ± 0.2
10.7 ± 5.5
versus
17.8 ± 8.2
1.97 ± 1.48
versus
2.8 ± 1.4
NA35.85 ± 24.3
versus
21.36 ± 7.57
Myo-Ins + D-chiro-Ins decreased significantly LH, free T levels, HOMA index, and fasting insulin. The combined treatment significantly increased E2 and SHBG. No relevant side effects were recorded. Therefore, the combined treatment, Myo-Ins + D-chiro-Ins, is effective in improving endocrine and metabolic parameters in young obese PCOS women.

Myo-Ins, myo-inositol; D-chiro-Ins, D-chiro-inositol; FA, folic acid; PCOS, polycystic ovary syndrome; PRL, prolactin; E2, oestradiol; A, androstenedione; 17OHP, 17-hydroxyprogesterone; T, testosterone; P, progesterone; OGTT, oral glucose tolerance; BMI, body mass index; LH, luteinizing hormone; FSH, follicle stimulating hormone; DHEAS, dehydroepiandrosterone; SHBG, sex hormone binding globulin; AUC, area under the curve of OGTT; VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; WHR, waist-to-hip ratio.
OGTT performed sampling 15 minutes before and 30, 60, 90, 120, and 240 minutes after the oral assumption of 75 g of glucose.
Values are mean ± SD. Values are mean ± SEM. Values are mean (CIs), confidence intervals (95%). A brief description is inserted in the table when numerical data are not available in the original article. The units were made uniform to show more comparable results.
value: ≤0.05; ≤0.01; ≤0.001: comparison posttreatment experimental group versus control.
value: ≤0.05; ≤0.01; ≤0.001: comparison posttreatment with respect to baseline. Data at baseline are not shown in the table.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.